Versant Capital Management, Inc
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 1735057
PHOENIX, AZ
Position in BCRX
as of Jun 30, 2026
· filed Jul 2, 2026
Position Value
$20,030
+$15,442 QoQ
Shares Held
2,003
+315.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#276
of 318 holders
Holding Since
Jun 2023
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Versant Capital Management, Inc holds $2,428,042 across 29 Drug Manufacturers - Specialty & Generic names. BCRX ranks #18 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TAK |
Takeda Pharmaceutical Co Ltd
|
42,686 | $684,256 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
10,265 | $347,778 | |
| 3 | ELAN |
Elanco Animal Health Inc
|
9,055 | $222,843 | |
| 4 | VTRS |
Viatris Inc
|
11,789 | $187,209 | |
| 5 | HLN |
Haleon plc
|
16,968 | $158,311 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
737 | $124,213 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
182 | $98,613 | |
| 8 | ZTS |
Zoetis Inc.
|
1,244 | $89,393 |
All Filings in BCRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,030 | 2,003 | Shares | Sole | 2026-07-02 | |
| 2026-03-31 | $4,588 | 482 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $1,201 | 154 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $1,168 | 154 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $1,379 | 154 | Shares | Sole | 2025-07-07 | |
| 2023-06-30 | $415 | 59 | Shares | Sole | 2023-07-10 | |
| No filing history on record for this holder in this stock. | ||||||